DYNAVAX TECHNOLOGIES CORP Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2025-09-11: Study NCT07207408; Company role Lead sponsor; Phase Phase 2; Status Recruiting.
- 2024-06-17: Study NCT06569823; Company role Lead sponsor; Phase Phase 1, Phase 2; Status Active not recruiting.
- 2022-08-09: Study NCT05506969; Company role Lead sponsor; Phase Phase 2; Status Completed.
- 2022-01-10: Study NCT05245838; Company role Lead sponsor; Phase Phase 1; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2025-09-11 | NCT07207408 Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age | Lead sponsor | Phase 2 | Recruiting | Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis | 148 | 2027-08-31 |
| 2024-06-17 | NCT06569823 Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over | Lead sponsor | Phase 1, Phase 2 | Active not recruiting | Shingles; Herpes Zoster; Vaccine-Preventable Diseases | 764 | 2031-11 |
| 2022-08-09 | NCT05506969 Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age | Lead sponsor | Phase 2 | Completed Results posted | Plague, Pneumonic; Plague; Vaccine-Preventable Diseases | 200 | 2024-04-26 |
| 2022-01-10 | NCT05245838 Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers | Lead sponsor | Phase 1 | Completed | Shingles; Herpes Zoster; Vaccine-Preventable Diseases | 150 | 2022-10-20 |
| 2021-02-21 | NCT03664648 DV2-HBV-27: Observational Pregnancy Registry | Lead sponsor | Observational | Unknown | Pregnant | 300 | 2024-12 |
| 2020-12-14 | NCT04193189 B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B | Collaborator Lead: National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 | Completed Results posted | HIV Infection; Hepatitis B | 638 | 2024-08-13 |
| 2020-06-01 | NCT04385524 Use of Dynavax Heplisav B in Healthcare Workers Previously Vaccinated With 3-dose Vaccine Who Failed to Demonstrate Seroprotection | Collaborator Lead: University of Louisville | Not applicable | Withdrawn | Hepatitis B Virus | 0 | 2021-02-28 |
| 2020-01-13 | NCT04177355 Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults | Collaborator Lead: National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | Completed Results posted | HIV Infections | 127 | 2024-11-04 |
| 2019-08-15 | NCT04050085 SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer | Collaborator Lead: University of California, Davis | Phase 1 | Completed | Metastatic Pancreatic Adenocarcinoma; Refractory Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8 | 6 | 2022-05-14 |
| 2019-04-22 | NCT03934736 HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis | Lead sponsor | Phase 1 | Completed Results posted | End Stage Renal Disease on Hemodialysis (Diagnosis) | 119 | 2021-09-15 |
| 2017-09-20 | NCT03326752 Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC | Lead sponsor | Phase 1 | Completed | Advanced Non Small Cell Lung Cancer | 26 | 2019-09-19 |
| 2015-09 | NCT02521870 A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Lead sponsor | Phase 1, Phase 2 | Terminated Results posted | Metastatic Melanoma; Head Neck Cancer | 241 | 2020-04 |
| 2014-10 | NCT02266147 Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma | Lead sponsor | Phase 1, Phase 2 | Terminated Results posted | B-cell Lymphoma | 29 | 2017-04 |
| 2014-04 | NCT02117934 Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine | Lead sponsor | Phase 3 | Completed Results posted | Healthy | 8,374 | 2015-10 |
| 2013-11 | NCT01999699 A Study of the Immune Response to Heplisav in Healthy Older Adults | Lead sponsor | Phase 1 | Completed | Hepatitis B | 25 | 2015-03 |
| 2010-12 | NCT01282762 Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease | Lead sponsor | Observational | Completed | Chronic Kidney Disease | 147 | 2013-08 |
| 2010-12 | NCT01195246 Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis | Lead sponsor | Phase 3 | Completed | End Stage Renal Disease | 155 | 2012-08 |
| 2010-02 | NCT01005407 Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine | Lead sponsor | Phase 3 | Completed Results posted | Healthy | 2,452 | 2011-05 |
| 2009-09 | NCT01023230 A Study to Assess DV-601 in Subjects With Chronic Hepatitis B | Lead sponsor | Phase 1 | Completed | Hepatitis B, Chronic | 14 | 2011-05 |
| 2009-09 | NCT00985426 Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients | Lead sponsor | Phase 3 | Completed Results posted | Chronic Kidney Disease | 521 | 2012-01 |
| 2008-10 | NCT00823862 Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection | Lead sponsor | Phase 1 | Completed | Chronic Hepatitis C | 34 | 2010-02 |
| 2008-01 | NCT00599001 Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males | Lead sponsor | Phase 1 | Completed | Healthy | 26 | 2008-03 |
| 2007-09 | NCT00537355 An Evaluation of the Efficacy and Safety of TOLAMBA™ for Ragweed-Allergic Rhinitis in an Environmental Exposure Chamber | Lead sponsor | Phase 2 | Completed | Rhinitis, Allergic, Seasonal | 271 | 2008-05 |
| 2007-07 | NCT00498212 A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal Disease | Lead sponsor | Phase 2 | Terminated | Hepatitis B | 41 | 2008-10 |
| 2007-06 | NCT00511095 Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine | Lead sponsor | Phase 2 | Completed Results posted | Hepatitis B | 207 | 2008-03 |
| 2006-12 | NCT00435812 Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine | Lead sponsor | Phase 3 | Completed Results posted | Hepatitis B | 2,428 | 2008-03 |
| 2006-11 | NCT00403052 A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer | Lead sponsor | Phase 1 | Terminated | Colorectal Neoplasms | 14 | 2007-12 |
| 2006-04 | NCT00387738 Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults | Lead sponsor | Phase 2 | Terminated | Rhinitis, Allergic, Seasonal | 738 | 2008-03 |
| 2006-01 | NCT00426712 Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients | Lead sponsor | Phase 1 | Completed | Hepatitis B | 42 | 2008-03 |
| 2004-07 | NCT00251394 Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma | Collaborator Lead: Dana-Farber Cancer Institute | Phase 2 | Completed | Non-Hodgkin's Lymphoma | 30 | 2009-07 |